A new publication by Boots UK and ScreenCancer highlights the benefits of ScreenCancer’s Mole Scanning Service in the pharmacy setting. The service evaluation has shown that the service, which offers customers the opportunity to have worrying skin lesions assessed by consultant dermatologists on a drop-in basis within community pharmacies, is effective at triaging patients and ultimately playing a part in identifying diagnoses of malignant melanoma. The study estimates that up to GBP 10m could be saved annually in the UK from avoided GP consultations if extending the service sufficiently to provide national coverage, not including additional benefits of additional measures of increasing awareness and prevention measures, and earlier diagnosis. The study also estimates that a further GBP 1.3m could be saved by allowing pharmacists to refer patients with suspicious lesions directly to dermatologists in secondary care.
More information about the publication can be found here:
DeepX Diagnostics Inc.'s DermoSight Receives FDA Clearance for Teledermatology Screening of Suspect Skin Cancer Lesions
Read moreDeepX Health to Present at the 8th World Congress of Teledermatology, Imaging and Artificial Intelligence for Skin Diseases
Read moreDeepX Health to participate at the 7th Annual Dermatology Summit in San Francisco
Read more